FDA gives orphan-drug designation to OXiGENE's leukemia drug

11/26/2012 | Pharmaceutical Business Review Online

The FDA granted orphan-drug status to OXiGENE's OXi4503, an experimental drug for acute myelogenous leukemia. The drug has demonstrated strong tumor-fighting activity in preclinical and clinical trials, CEO Peter Langecker said. OXiGENE plans to apply for orphan drug designation in the European Union. An early-stage trial is being backed by the Leukemia & Lymphoma Society.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT